Table 1.
Critical appraisal of included studies and description of biomarkers
| Study | SP | SA | PF | O | C | AR | B | HIF-1a | HIF-2a | CA-IX | GLUT-1 | OPN |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aebersold et al. 20 | L | H | L | L | M | L | 1 | • | ||||
| Avirović et al. 35 | M | L | M | L | M | L | 3 | • | ||||
| Brockton et al. 48 | L | H | M | L | M | L | 2 | • | ||||
| Brockton et al. 33 | M | H | M | L | M | L | 3 | • | • | |||
| Cabanillas et al. 53 | H | H | L | L | M | L | 3 | • | ||||
| Chien et al. 36 | H | H | L | L | L | M | 3 | • | ||||
| Chien et al. 37 | M | L | L | L | M | L | 2 | • | ||||
| Choi et al. 57 | M | H | L | L | M | M | 3 | • | ||||
| Choi et al. 38 | M | L | L | L | M | M | 3 | • | ||||
| Dos Santos et al. 39 | M | L | L | L | L | M | 2 | • | ||||
| Douglas et al. 22 | L | H | L | L | L | L | 0 | • | • | |||
| Dunkel et al. 40 | L | H | L | L | M | M | 2 | • | ||||
| Eckert et al. 41 | H | L | L | L | M | L | 3 | • | • | |||
| Eckert et al. 42 | H | L | L | L | L | L | 2 | • | • | |||
| Eriksen et al. 61 | L | L | L | L | L | L | 0 | • | ||||
| Fillies et al. 49 | H | H | M | L | L | L | 3 | • | ||||
| Grimm et al. 44 | H | L | L | L | M | L | 3 | • | ||||
| Hong et al. 56 | L | L | L | L | L | L | 0 | • | ||||
| Hui et al. 31 | L | H | L | L | L | L | 0 | • | • | |||
| Jonathan et a. 30 | M | L | L | L | L | L | 1 | • | • | |||
| Kim et al. 51 | H | L | M | L | L | L | 3 | • | ||||
| Kitagawa et al. 32 | H | L | M | L | L | L | 3 | • | ||||
| Kwon et al. 23 | H | L | L | L | M | L | 3 | • | • | • | ||
| Le et al. 58 | H | L | M | L | L | L | 3 | • | • | |||
| Liang et al. 45 | L | H | L | L | H | L | 2 | • | • | |||
| Nordsmark et al. 29 | M | L | L | L | M | M | 3 | • | • | • | ||
| Pérez-Sayáns et al. 55 | M | L | L | L | M | M | 3 | • | ||||
| Rademakers et al. 24 | M | L | M | L | L | L | 2 | • | ||||
| Rahimi et al. 60 | L | H | L | L | L | L | 0 | • | • | |||
| Roh et al. 52 | L | L | M | L | M | L | 2 | • | • | • | ||
| Schrijvers et al. 25 | L | L | M | L | L | L | 1 | • | • | • | ||
| Silva et al. 21 | M | H | L | L | M | L | 2 | • | ||||
| Van den Broek (2009) | L | H | M | L | L | L | 1 | • | • | |||
| Wachters et al. 26 | L | H | L | L | L | L | 0 | • | • | • | ||
| Wan et al. 59 | M | H | M | L | L | L | 2 | • | ||||
| Wildeman et al. 27 | M | L | L | L | M | L | 2 | • | • | |||
| Winter et al. 54 | M | L | L | L | M | L | 2 | • | • | • | ||
| Xueguan et al. 28 | L | L | L | L | M | M | 2 | • | ||||
| Zheng et al. 46 | M | H | L | L | M | M | 3 | • | ||||
| Zhu et al. 47 | L | H | M | L | L | L | 1 | • | • | |||
| Totals | 27 | 3 | 21 | 7 | 6 |
Low, 0; Moderate, 1; High, 2 points. SA was not included. Studies with a bias score >3 were excluded. Appraisal of these studies is described in supplementary table S2. SP, study participation; SA, study attrition; PF, prognostic factor; O, Outcome; C, Confounding; AR, statistical analysis and reporting. B, Bias score according to QUIPS; HIF-1, hypoxia-inducible factor 1. The EMHs that were described in each study are shown with a filled dot (example of filled dot).